Pfizer, Merck company sites winning battle for docs

Share this article:

Corporate Web sites from pharmaceutical firms with broad portfolios draw the most primary care physicians on a regular basis, new research shows.
Pfizer.com and Merck.com command 50 percent and 44 percent of the market share, respectively, according to the 2005 ePharma Physician study of 48 Web sites from Manhattan Research. Market share was measured as a function of total number of U.S. physician visitors, out of 1,251 surveyed, compared with frequency. Eli Lilly (25 percent), GlaxoSmithKline (24 percent) and Novartis (22 percent) round out the top five most visited by PCPs.
Companies with more targeted portfolios, like Berlex and Organon, rank above average on relevance among PCPs and specialists, perhaps because they know their audience and are able to provide rich, relevant content, said Manhattan Research vice president of research Meredith Abreu.
As far as product Web sites, GSK's asthma drug portal Advair.com garners the highest share among general practitioners, with 18 percent, followed by Allegra.com, the allergy product site from Aventis Pharmaceuticals, at 15 percent.
Seventy percent of the 606,000 practicing U.S. physicians have used technology such as e-detailing or e-sampling; have visited a pharma or related website in the last year; or searched for Rx or related information online in the last month.
Some segments also rely primarily on physician-targeted portals, such as Medscape, MDConsult, UpToDate and MerckMedicus, which has a 20 percent to 25 percent overall reach among physicians and is especially read by high-prescribing PCPs.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...